Phase I Clinical Trial and Pharmacokinetic Study

infusion solutions are compatible with PVC i.v. infusion bags and are chemically stable ... two cycles of treatment. Disease assessments by any tech- ...

2 downloads 0 Views 168KB Size

Recommend Documents

Apr 9, 2017 - to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.

In a phase 2 study of raltitrexed, cisplatin, and 5- fluorouracil administered to .... nitroacetanilide, was obtained from Sigma-Aldrich (Milwaukee,. WI). Twenty-five ...

Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with. Advanced Cancer1. Sridhar Mani,2 ...

Val and 5-methylbenzoic acid form the lateral chain. The cycled region ...... (M)/prednisone (P) in men with androgen independent prostate cancer. J Clin Oncol ...

(/')determined the human pharmacokinetics of the drug on a. 6-h infusion ..... dexamethasone, and/or aminophylline were required to treat the reactions.

POH was formulated in soft gelatin capsules con- .... Drug Formulation. ... phase I design. .... No significant problems with myelosuppression were seen. Grade 1 ...

staurosporine family of agents, which have two indole nitrogens linked to a carbohydrate residue. Representatives from both of these subgroups have been the ...

p.o., but this route of administration has several limitations. The bioavailability of MP is low. (approximately. 16%), and the resulting plasma concen- trations exhibit ..... for the tram- fer ofTG toand from the peripheral compartment;. Xe,, the am

in Serum of Cancer Patients: Phase I Clinical Trial. Jose A. Baptista,1 ... (1), sub- sequently from. North. American plants of the ganera. Astragulus .... Gal in H20.

Center, Salt Lake City, UT; Grant CA 26126, Robert Wells of the. Children's Hospital ..... Giguere, V., Ong, E. S., Segui, P., and Evans, R. M. Identification of a receptor for the .... Brazell, R. K., Vane, F. M., Ehmann, C. W., and Colburn, W. A..

Robert J. Motzer,2 Subhash C. Gulati, William P.Tong, Celia Menendez-Botet, Peter ... •'the Department of Clinical Chemistry [C. M-B.j: and the Department of ...

Jul 15, 2006 - suggested that G1 arrest induced by EGFR TKI interferes with the cell cycle .... Dassonville O, Formento JL, Francoual M, et al. Expression of ...

derived from breast (MDA-MB-435), colorectal (RKO, HT-29, ..... 2019. 625. 1857. 1077. 4208. 2903. 2434. Ctrough e (ng/ml). Ro 31-7453. 54.2. 145. 72. 361.

May 15, 2009 - Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour ... Authors' Affiliations: 1Institute for Drug Development, Cancer Therapy ...

feasibility, toxicity, and pharmacokinetics of an escalating dose of docetaxel when ...... This contrasts with the nonlinear pharmacokinetic profile of paclitaxel (20).

Oct 13, 2009 - pared with prior studies of the parental antibody hu3S193. These results ... humanized monoclonal antibody based on the anti-Ley anti-.

Abstract. Purpose: VNP40101M is a novel sulfonylhydrazine al- kylating agent with broad antitumor activity in animal mod- els. As alkylating agents are ...

Dec 15, 2005 - Anthony W.Tolcher,1and Eric K. Rowinsky1. Abstract Purpose:To ...... Tricoli JV, Sahai BM, McCormick PJ, Jarlinski SJ,. Bertram JS, Kowalski D.

Department of Medicine [L. M. K., K. K. N., M. G. K., V. A. M.,. J. K.], Program of Molecular ... the Simon Benlevy Cancer Fund. 2 To whom requests for reprints ...

This regimen deserves further evaluation to define its antitumor activity .... DLT was defined as any of the ..... Karenitecin is the first compound of this type to be.

liters/h/m2 (n = 6; P < 0.002), denoting a departure from linear pharma- cokinetic behavior. The rather low steady ... ~To whom requests for reprints should be addressed, at the Laboratory of Pharma ceutical Chemistry, National ...... As anticipated

would experience grade 3 or 4 toxicity, and thus to define a dose suitable for broad phase II evaluation. ...... (D-19466; lobaplatin) admin istered daily for 5 days.

Apr 1, 1994 - nitrogen is believed to be the mechanism ... Doses of sodium phenylacetate to be infused over 30 min to 2 h were prepared in 150 ml .... posed of two pumps (305 and 306), an 805 manometric module, an 811C dynamic mixer ...

treatment of multiple myeloma, ovarian cancer, breast cancer, and neuroblastoma (3–5). .... ferases, -glutamyl-aminotransferase, alkaline phosphatase, and.